SCHEMBL22345489

SCHEMBL22345489

CC(C)c1ccc(-c2ccccc2)cc1C(=O)N1CCC(O)(Cn2cnn3cccc3c2=O)CC1

nearest known ligand 0.73

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
USP7 Q93009 20/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22345596 0.90 USP7 (0.75) USP7
SCHEMBL22345567 0.88 USP7 (0.72) USP7
SCHEMBL17893855 0.87 USP7 (0.74) USP7
SCHEMBL17868550 0.86 USP7 (0.83) USP7
SCHEMBL22345570 0.86 USP7 (0.72) USP7
SCHEMBL22345558 0.86 USP7 (0.72) USP7
SCHEMBL17868430 0.85 USP7 (0.85) USP7
SCHEMBL17868455 0.84 USP7 (1.00) USP7
SCHEMBL17868524 0.84 USP7 (0.83) USP7
SCHEMBL17868403 0.83 USP7 (0.73) USP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3923987-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2021-12-22 EP disclosed
WO-2020165315-A1 USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2020-08-20 WO disclosed